.png)
Why entity-owned pharmacies kept their IRA drug volume in the first full quarter under the Maximum Fair Price—and contract pharmacy channels didn't
Two pharmacies dispensed the same IRA drugs, in the same quarter, under the same rules. One kept its volume. The other walked away from it. The gap between them is the most useful thing we've seen in our network data all year.
The reason we can see it at all is that Mission Control sits on top of the whole network—entity-owned and contract pharmacy, drug by drug.
Charlie Hirner, who leads it, walked us through exactly what the first-quarter data shows. It runs just over a minute, and it's worth watching before you read the rest:
"You actually saw claim volume increasing of the IRA drugs at entity-owned pharmacies. But conversely, about 18.5% of volume dried up… because contract pharmacy partners decided to carve these out. They didn't know how to manage it." —Charlie Hirner, SVP, Mission Control
Here's how the two channels compared across our covered entities—the first quarter under the Maximum Fair Price against the same quarter the year before:
Entity-owned pharmacies took the margin hit and held their ground. Their IRA-drug claims grew 22.5%. Their margin per claim fell hard—from $633 to $338, a 47% drop—but the volume growth absorbed part of the blow. On their total 340B book, claims rose 10.6% while margin slipped 10.2%. They leaned in.
Contract pharmacy channels did the opposite. IRA-drug claims fell 18.5%, and the margin on what remained dropped 53%, from $416 to $197. When a drug stopped paying, the contract channel stopped dispensing it.
Why did the two channels react so differently?
When the Maximum Fair Price landed January 1, the contract-pharmacy channels had to react fast, and many simply carved the affected IRA drugs out: filtering by payer, by Part D, drug by drug, to pull them from the program.
As Charlie puts it, "they didn't know how to manage it." Not malice—the speed of a rule change colliding with systems that weren't ready. The entity-owned pharmacy did the opposite: it carved the drugs in, took the margin hit, and kept the 340B revenue.
Neither choice is wrong. They're different answers to the same question: what do you do when Medicare drug price negotiation compresses the margin on drugs your patients still need?
The entity-owned answer is the one worth studying.
What "carving in" actually buys a covered entity
When you own the pharmacy, the decision isn't "is this script profitable enough to keep." It's "this is our patient, and we're keeping the relationship." The margin compressed, but the patient stayed, the data stayed, and the channel stayed open for the day the economics reset. That's not a small thing.
As Charlie notes, 340B pricing will reset as ASP levels out, and a reasonable margin returns. When that floor stops moving, the entity that kept its volume is positioned to recover. The entity in a channel that carved out has to win the patient back first.
Why most TPAs can't see this pattern
Most TPAs only see their own slice. We see roughly 700 FQHCs, every major chain partner, and all three dispensing channels—contract pharmacy, referral capture, and entity-owned.
That's how you spot a pattern like this: not because we're smarter, but because we see more. More than 1.5 billion claims tell you what the top-performing entities do differently before it shows up in your own numbers.
What FQHCs and 340B hospitals should do about it
So the strategy Charlie lands on is the one to sit with: grow your capture of Medicare patients at your entity-owned pharmacy. That's the most direct way to prevent further erosion on these IRA drugs down the road.
The question underneath it is narrower and more useful than "how bad was the IRA."
It's this: when a rule changes overnight, can you see what got carved out of every channel, or only the one you own?
The entities that kept the patient relationship are the ones with something left to reinvest—another pharmacist on staff, extended hours, a specialty line that funds itself.
The storm hit everyone. What you keep depends on which channel was holding the umbrella.
Want to see how your entity-owned and contract channels compare to the network?
Let’s look at your numbers.
Frequently asked
What are IRA drugs in 340B?
IRA drugs are the ten Medicare-negotiated medications that became subject to the Maximum Fair Price on January 1, 2026, under the Inflation Reduction Act's Drug Price Negotiation Program. For 340B-covered entities, the MFP compressed margins by 47%–53% on those drugs in the first full quarter under the new pricing.
Entity-owned vs. contract pharmacy—what's the difference in a 340B program?
An entity-owned pharmacy is operated directly by the 340B-covered entity (FQHC, Ryan White clinic, or hospital). A contract pharmacy is a third-party retail pharmacy dispensing 340B prescriptions on behalf of the covered entity under contract. The two channels made very different bets when the MFP hit: entity-owned pharmacies grew IRA-drug volume 22.5%; contract channels dropped 18.5%.
Data insights from Charlie Hirner, SVP, Mission Control at NuvemRx.